Clinical efficacy and safety of combined induction therapy with rituximab and ATG in highly sensitized kidney transplant recipients
To summarize the efficacy and safety of the combination of rituximab and ATG as induction therapy in highly sensitized kidney transplant recipients. Clinical data of patients who received kidney transplantation from donation after cardiac death(DCD) in Organ Transplant Center of Second Affiliated Ho...
Gespeichert in:
| Veröffentlicht in: | Zhong hua yi xue za zhi 2019-04, Vol.99 (16), p.1232-1236 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1236 |
|---|---|
| container_issue | 16 |
| container_start_page | 1232 |
| container_title | Zhong hua yi xue za zhi |
| container_volume | 99 |
| creator | Fang, J L Chen, Z Guo, Y H Ma, J J Pan, G H Li, G H Xu, L Zhang, L Lai, X X Yin, W Yao, Z P Chen, L B |
| description | To summarize the efficacy and safety of the combination of rituximab and ATG as induction therapy in highly sensitized kidney transplant recipients.
Clinical data of patients who received kidney transplantation from donation after cardiac death(DCD) in Organ Transplant Center of Second Affiliated Hospital of Guangzhou Medical University from January 1st 2015 to December 31th 2016 was retrospectively analyzed. Highly sensitized patients with over 30% active panel reactive antibody (PRA>30%) received rituximab, while non-sensitized recipients as controlled group. All selected patients were observed in the renal function, urine protein, hemogram and the variation of PRA at each time point. Acute rejection, infection required hospitalization, delayed graft function(DGF), primary nonfunction (PNF), graft dysfunction, the mortality rate of patients with good allograft function and the graft survival rate were also observed.
46 groups of patients were selected into highly-sensitized group and non-sensitized group. I |
| doi_str_mv | 10.3760/cma.j.issn.0376-2491.2019.16.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2231919887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2231919887</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-6e417a668a7e72cddeb00ee6214de34e8c77aa448194100c5c665b294656a35d3</originalsourceid><addsrcrecordid>eNo9kDFPwzAUhD2AaAX9C8hjlwbbcZxkrCooSJVYyhw59gt5kDghdgRh5Y8TQWE66fTd090jZM1ZFKeK3ZhWRy8Reu8iNhsbIXMeCcbziKuIseyMLP_9BVl5jyWTaZwLJvgFWcScKcaVWJKvXYMOjW4oVNWsZqLaWep1BWGiXUVN15bowFJ0djQBO0dDDYPuJ_qOoaYDhvEDW13-5LbH_QzSGp_rZqIenMeAn3P6Fa2DiYZBO9832gU6gMEewQV_Rc4r3XhYnfSSPN3dHnf3m8Pj_mG3PWx6LlTYKJA81UplOoVUGGuhZAxACS4txBIyk6ZaS5nxXHLGTGKUSkqRS5UoHSc2viTr37v90L2N4EPRojfQzHWgG30hRMxznmdZOqPXJ3QsW7BFP8wTh6n4e1z8DbOcdY8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2231919887</pqid></control><display><type>article</type><title>Clinical efficacy and safety of combined induction therapy with rituximab and ATG in highly sensitized kidney transplant recipients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Fang, J L ; Chen, Z ; Guo, Y H ; Ma, J J ; Pan, G H ; Li, G H ; Xu, L ; Zhang, L ; Lai, X X ; Yin, W ; Yao, Z P ; Chen, L B</creator><creatorcontrib>Fang, J L ; Chen, Z ; Guo, Y H ; Ma, J J ; Pan, G H ; Li, G H ; Xu, L ; Zhang, L ; Lai, X X ; Yin, W ; Yao, Z P ; Chen, L B</creatorcontrib><description>To summarize the efficacy and safety of the combination of rituximab and ATG as induction therapy in highly sensitized kidney transplant recipients.
Clinical data of patients who received kidney transplantation from donation after cardiac death(DCD) in Organ Transplant Center of Second Affiliated Hospital of Guangzhou Medical University from January 1st 2015 to December 31th 2016 was retrospectively analyzed. Highly sensitized patients with over 30% active panel reactive antibody (PRA>30%) received rituximab, while non-sensitized recipients as controlled group. All selected patients were observed in the renal function, urine protein, hemogram and the variation of PRA at each time point. Acute rejection, infection required hospitalization, delayed graft function(DGF), primary nonfunction (PNF), graft dysfunction, the mortality rate of patients with good allograft function and the graft survival rate were also observed.
46 groups of patients were selected into highly-sensitized group and non-sensitized group. I</description><identifier>ISSN: 0376-2491</identifier><identifier>DOI: 10.3760/cma.j.issn.0376-2491.2019.16.008</identifier><identifier>PMID: 31060162</identifier><language>chi</language><publisher>China</publisher><subject>Antilymphocyte Serum ; Graft Rejection ; Graft Survival ; Humans ; Immunosuppressive Agents ; Kidney Transplantation ; Retrospective Studies ; Rituximab ; Treatment Outcome</subject><ispartof>Zhong hua yi xue za zhi, 2019-04, Vol.99 (16), p.1232-1236</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31060162$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fang, J L</creatorcontrib><creatorcontrib>Chen, Z</creatorcontrib><creatorcontrib>Guo, Y H</creatorcontrib><creatorcontrib>Ma, J J</creatorcontrib><creatorcontrib>Pan, G H</creatorcontrib><creatorcontrib>Li, G H</creatorcontrib><creatorcontrib>Xu, L</creatorcontrib><creatorcontrib>Zhang, L</creatorcontrib><creatorcontrib>Lai, X X</creatorcontrib><creatorcontrib>Yin, W</creatorcontrib><creatorcontrib>Yao, Z P</creatorcontrib><creatorcontrib>Chen, L B</creatorcontrib><title>Clinical efficacy and safety of combined induction therapy with rituximab and ATG in highly sensitized kidney transplant recipients</title><title>Zhong hua yi xue za zhi</title><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><description>To summarize the efficacy and safety of the combination of rituximab and ATG as induction therapy in highly sensitized kidney transplant recipients.
Clinical data of patients who received kidney transplantation from donation after cardiac death(DCD) in Organ Transplant Center of Second Affiliated Hospital of Guangzhou Medical University from January 1st 2015 to December 31th 2016 was retrospectively analyzed. Highly sensitized patients with over 30% active panel reactive antibody (PRA>30%) received rituximab, while non-sensitized recipients as controlled group. All selected patients were observed in the renal function, urine protein, hemogram and the variation of PRA at each time point. Acute rejection, infection required hospitalization, delayed graft function(DGF), primary nonfunction (PNF), graft dysfunction, the mortality rate of patients with good allograft function and the graft survival rate were also observed.
46 groups of patients were selected into highly-sensitized group and non-sensitized group. I</description><subject>Antilymphocyte Serum</subject><subject>Graft Rejection</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>Immunosuppressive Agents</subject><subject>Kidney Transplantation</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Treatment Outcome</subject><issn>0376-2491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kDFPwzAUhD2AaAX9C8hjlwbbcZxkrCooSJVYyhw59gt5kDghdgRh5Y8TQWE66fTd090jZM1ZFKeK3ZhWRy8Reu8iNhsbIXMeCcbziKuIseyMLP_9BVl5jyWTaZwLJvgFWcScKcaVWJKvXYMOjW4oVNWsZqLaWep1BWGiXUVN15bowFJ0djQBO0dDDYPuJ_qOoaYDhvEDW13-5LbH_QzSGp_rZqIenMeAn3P6Fa2DiYZBO9832gU6gMEewQV_Rc4r3XhYnfSSPN3dHnf3m8Pj_mG3PWx6LlTYKJA81UplOoVUGGuhZAxACS4txBIyk6ZaS5nxXHLGTGKUSkqRS5UoHSc2viTr37v90L2N4EPRojfQzHWgG30hRMxznmdZOqPXJ3QsW7BFP8wTh6n4e1z8DbOcdY8</recordid><startdate>20190423</startdate><enddate>20190423</enddate><creator>Fang, J L</creator><creator>Chen, Z</creator><creator>Guo, Y H</creator><creator>Ma, J J</creator><creator>Pan, G H</creator><creator>Li, G H</creator><creator>Xu, L</creator><creator>Zhang, L</creator><creator>Lai, X X</creator><creator>Yin, W</creator><creator>Yao, Z P</creator><creator>Chen, L B</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20190423</creationdate><title>Clinical efficacy and safety of combined induction therapy with rituximab and ATG in highly sensitized kidney transplant recipients</title><author>Fang, J L ; Chen, Z ; Guo, Y H ; Ma, J J ; Pan, G H ; Li, G H ; Xu, L ; Zhang, L ; Lai, X X ; Yin, W ; Yao, Z P ; Chen, L B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-6e417a668a7e72cddeb00ee6214de34e8c77aa448194100c5c665b294656a35d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2019</creationdate><topic>Antilymphocyte Serum</topic><topic>Graft Rejection</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>Immunosuppressive Agents</topic><topic>Kidney Transplantation</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Fang, J L</creatorcontrib><creatorcontrib>Chen, Z</creatorcontrib><creatorcontrib>Guo, Y H</creatorcontrib><creatorcontrib>Ma, J J</creatorcontrib><creatorcontrib>Pan, G H</creatorcontrib><creatorcontrib>Li, G H</creatorcontrib><creatorcontrib>Xu, L</creatorcontrib><creatorcontrib>Zhang, L</creatorcontrib><creatorcontrib>Lai, X X</creatorcontrib><creatorcontrib>Yin, W</creatorcontrib><creatorcontrib>Yao, Z P</creatorcontrib><creatorcontrib>Chen, L B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhong hua yi xue za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fang, J L</au><au>Chen, Z</au><au>Guo, Y H</au><au>Ma, J J</au><au>Pan, G H</au><au>Li, G H</au><au>Xu, L</au><au>Zhang, L</au><au>Lai, X X</au><au>Yin, W</au><au>Yao, Z P</au><au>Chen, L B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical efficacy and safety of combined induction therapy with rituximab and ATG in highly sensitized kidney transplant recipients</atitle><jtitle>Zhong hua yi xue za zhi</jtitle><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><date>2019-04-23</date><risdate>2019</risdate><volume>99</volume><issue>16</issue><spage>1232</spage><epage>1236</epage><pages>1232-1236</pages><issn>0376-2491</issn><abstract>To summarize the efficacy and safety of the combination of rituximab and ATG as induction therapy in highly sensitized kidney transplant recipients.
Clinical data of patients who received kidney transplantation from donation after cardiac death(DCD) in Organ Transplant Center of Second Affiliated Hospital of Guangzhou Medical University from January 1st 2015 to December 31th 2016 was retrospectively analyzed. Highly sensitized patients with over 30% active panel reactive antibody (PRA>30%) received rituximab, while non-sensitized recipients as controlled group. All selected patients were observed in the renal function, urine protein, hemogram and the variation of PRA at each time point. Acute rejection, infection required hospitalization, delayed graft function(DGF), primary nonfunction (PNF), graft dysfunction, the mortality rate of patients with good allograft function and the graft survival rate were also observed.
46 groups of patients were selected into highly-sensitized group and non-sensitized group. I</abstract><cop>China</cop><pmid>31060162</pmid><doi>10.3760/cma.j.issn.0376-2491.2019.16.008</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0376-2491 |
| ispartof | Zhong hua yi xue za zhi, 2019-04, Vol.99 (16), p.1232-1236 |
| issn | 0376-2491 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_2231919887 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antilymphocyte Serum Graft Rejection Graft Survival Humans Immunosuppressive Agents Kidney Transplantation Retrospective Studies Rituximab Treatment Outcome |
| title | Clinical efficacy and safety of combined induction therapy with rituximab and ATG in highly sensitized kidney transplant recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T22%3A19%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20efficacy%20and%20safety%20of%20combined%20induction%20therapy%20with%20rituximab%20and%20ATG%20in%20highly%20sensitized%20kidney%20transplant%20recipients&rft.jtitle=Zhong%20hua%20yi%20xue%20za%20zhi&rft.au=Fang,%20J%20L&rft.date=2019-04-23&rft.volume=99&rft.issue=16&rft.spage=1232&rft.epage=1236&rft.pages=1232-1236&rft.issn=0376-2491&rft_id=info:doi/10.3760/cma.j.issn.0376-2491.2019.16.008&rft_dat=%3Cproquest_pubme%3E2231919887%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2231919887&rft_id=info:pmid/31060162&rfr_iscdi=true |